Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P0DI81
UPID:
TPC2A_HUMAN
Alternative names:
Sedlin
Alternative UPACC:
P0DI81; A6NEG0; O14582; Q9HD16
Background:
Trafficking protein particle complex subunit 2, also known as Sedlin, plays a crucial role in cellular processes, including preventing transcriptional repression and induction of cell death by ENO1, and facilitating vesicular transport from the endoplasmic reticulum to the Golgi. Its involvement in these processes underscores its importance in maintaining cellular homeostasis.
Therapeutic significance:
Sedlin is directly associated with Spondyloepiphyseal dysplasia tarda, an X-linked recessive disorder of endochondral bone formation. This connection highlights the protein's potential as a target for therapeutic intervention in treating this genetic condition.